Articles On Oventus Medical (ASX:OVN)

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Mayne Pharma launches a new line of women contraceptive in the US Oventus’ administrators have gone to work   Mayne Pharma (ASX: MYX) and Brussels-listed Mithra Pharma announced the launch of HALOETTE, a vaginal hormonal contraceptive rin...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

After 35 years of stockbroking for some of the biggest houses and investors in Australia and the UK, the Secret Broker is regaling Stockhead readers with his colourful war stories — from the trading floor to the dealer’s desk. Here is a lis...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Benchmark collapses Small caps down 6% Hamelin brings hope   After a really terrific Queen’s Birthday long weekend, local markets already had a session of losses to catch up on at the open. Needless to say, they have. The benchmark took...

Emerging companies fall 0.7% ASX200 0.8% lower Superior Resources (ASX:SPQ) jumps on copper system find, Galileo up … heaps in May   The Emerging Companies (XEC) index is lower on Thursday, weighed down by broad losses as Credit Suisse a...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The preferred, often heroic index of the Australian small cap, The Emerging Companies XEC has shed 2.4% today, to add to the haemorrhaging of the last four weeks. The ASX200 (XJO) has closed just 0.2% lower. If this is a cash rate thing, wh...

The preferred, often heroic index of the Australian small cap, The Emerging Companies XEC has shed 2.4% today, to add to the haemorrhaging of the last four weeks. The ASX200 (XJO) has closed just 0.2% lower. If this is a cash rate thing, wh...

The interest rate rise came and the markets fell, then turned a corner. The question now is — will the wheels stay on? Already lagging, the ASX Emerging Companies (XEC) index has closed 0.8% lower. The benchmark has closed 0.4% behind. The...

Central Banks have their fingers on the fun button this week, and the markets are pricing in the big push. The Emerging Companies Index (XEC) has been sunk on day dot, down 2.3%. The S&P/ASX 200 index was down 1.2% at 4.15pm, with this...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

ASX Emerging Companies (XEC) Index is about 1.25% higher ahead of the close on Monday Iron ore shakes $US160, Aussie rattles US75¢ Major movers today: Top End Energy (ASX:TEE), Golden Deeps (ASX:GED), Sayona Mining (ASX:SYA)   The ASX Eme...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

The ASX Emerging Companies index (XEC) is up more than 1.5% on Thursday, while the benchmark ASX 200 is higher as well. Local investors are totally unconcerned by weak US futures when commodity prices behave like incensed lemmings. The alre...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

The ASX 200 rose 0.64% on the first trading day of the month. All sectors were in the green except financials – a sector dragged down by Westpac (ASX:WBC) following its results. The best sectors were consumer discretionaries, telcos and uti...

The biggest director trade on the ASX in the past fortnight came from one of Australia’s most famous pub barons – Bruce Mathieson of Endeavour Group (ASX:EDV). Mathieson is 63rd on the Top 22 rich list with a net worth of $1.54 billion. End...

The ASX limped into the close on Friday, in a fairly tame finish to a roller-coaster week. Evergrande contagion fears and jitters ahead of the US Fed meeting sparked a sharp selloff on Monday. But a week (or three days) is a long time in ma...

Once again the energy sector determined the direction of the market but unlike yesterday where it gained, today it finished in the red. The ASX 200 retreated 0.27% to close at 7,417 points, although the ASX Emerging Companies Index rose 1.3...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Trading Places is Stockhead’s recap of the buys and sells of ASX small cap shares by fund managers and other famous investors over the last fortnight. Specifically, Stockhead tracks substantial shareholder movements, being shareholders hold...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Trading Places is Stockhead’s recap of the buys and sells of ASX small cap shares by fund managers and other famous investors over the last fortnight. Specifically, Stockhead tracks substantial shareholder movements, being shareholders hold...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

If you want to know which ASX stocks fund managers and famous investors are putting their money into we’ve been keeping track of substantial holder buys (and sells). Trading Places is Stockhead’s recap of the substantial holder movements am...

Summary ASX-listed digital health company ResApp Health has recruited the first participant in its US-based trial to assess the link between cough and COVID-19. Botanix Pharmaceuticals revealed encouraging results from the BTX 1204A Pi...

This week’s Hot Money is more or less brought to you by the good folks at Mindax (ASX:MDX), with a nice cameo from Australia’s only listed football team. Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relati...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Healthcare...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

The ASX finished the day in the red and the tech sector dropped more than any other sector. The ASX 200 closed at 7,062 which was 0.48 per cent down from yesterday and tech stocks shed over 3.5 per cent. The only other sector to fall over 1...